Abstract
Over the recent years, targeted therapy has become one of the most important innovations in cancer treatment. Agents targeting the epidermal growth factor receptor (EGFR) are administered in patients with advanced, recurrent, and metastatic malignancy. Skin toxicity is one of the most common side effects of EGFR inhibitors. In this report, we present the case of a 70 year-old male patient with metastatic colorectal cancer who developed an intertrigo-like eruption during molecular target therapy with cetuximab treated with topical corticosteroid. A complete remission was obtained after 4 weeks.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
